S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68

Follow The Money To Cigna

Tuesday, May 10, 2022 | Thomas Hughes
Follow The Money To Cigna

Cigna Falls On Strong Results, Analyst Upgrade 

It is times like this when following the money can give the best returns and the money is flowing toward Cigna (NYSE: CI). The company released a better than expected earnings report and raised its guidance sparking yet another wave of analysts upgrades and price target revisions. The latest includes at least 7 post-release commentaries with 7 price target upgrades and a new high price target as well. The high price target comes from Cowen which upgraded the stock to Outperform citing a number of catalysts for higher share prices. Among them are the stock's low valuation, an inflation-induced tailwind for managed healthcare, increasing market share, and an oncoming wave of biosimilar medications that will drive revenue for the pharmacy segment

Cowen’s price target of $329 is up from the previous $262 and compares very well to the Marketbeat.com consensus of $276. The consensus is only 5% above the current price action compared to almost 25% for Cowen’s target but the consensus is trending higher. Assuming the other 16 analysts following the stock see similar catalysts in store for the company there should be a few more upgrades and/or price targets at least. Until then, the stock is rated as a firm Buy by the analyst community. 

Cigna Beats And Raises Guidance For 2022

Cigna had a great quarter supported by strength across all business segments. The company reported $44.01 billion in net revenue for a gain of 7.4% over last year. The revenue also beat the Marketbeat.com consensus by 120 basis points and the good news does not end there. Moving down to the earnings, both segments contributed to earnings power and a YOY increase in margin. Digging a little deeper, a 180 basis point improvement in Cigna margin was offset by a 10 basis point contraction in Evernorth and both are better than expected. The  $6.01 in adjusted EPS is up from last year’s $4.73 and a company record

Turning to the guidance, the company raised its revenue target to at least $177 billion versus the consensus of $179 but it is the earnings guidance that has us interested. The adjusted EPS is expected to be at least $22.60 versus the consensus of $22.49 which is very good news for shareholders. The company is using its capital to buy back shares and pay a dividend that we view as growing. The company has only increased the distribution for two years but there is ample room in the numbers and earnings growth in the forecast. In our view, the company may not continue the 150% CAGR it has set but a healthy double-digit pace of increase is a reasonable expectation. 

The Technical Outlook: Cigna Might Have Just Peaked Out 

Institutional buying has been supporting Cigna's price action for years but the market may have just topped out. While the institutional activity has been net bullish over the last year it has been fairly balanced and not the support it has been in the past. This may keep price action from moving much higher in the near term but the long-term outlook is still bullish. In the near-term, price action may move sideways within the newly established range of $240 to $280 before setting a new high. The risk is that institutional support will fail and we don’t see that happening right now, not with the stock trading at 10X its earnings and yielding 1.7%. Longer-term, we see Cigna completing a consolidation at the current levels and then moving up to new highs as revenue, earnings, and capital returns grow. 

Follow The Money To Cigna And Be Rewarded 

Should you invest $1,000 in Cigna right now?

Before you consider Cigna, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cigna wasn't on the list.

While Cigna currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The 5 Stocks Here


Companies Mentioned in This Article

CompanyMarketRank™Current PricePrice ChangeDividend YieldP/E RatioConsensus RatingConsensus Price Target
Cigna (CI)
2.8328 of 5 stars
Compare These Stocks  Add These Stocks to My Watchlist 


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.